{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T14:33:28Z","timestamp":1778855608701,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,9,19]],"date-time":"2017-09-19T00:00:00Z","timestamp":1505779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,9,19]],"date-time":"2017-09-19T00:00:00Z","timestamp":1505779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Sodium\u2013glucose cotransporter 2 (SGLT2) inhibitors are oral antidiabetic drugs that promote urinary glucose excretion. Conversely, they cause behavioural changes, such as hyperphagia, that result in a positive energy balance. The relationship between energy homeostasis and SGLT2 inhibitors-induced behavioural changes remains unclear. Here we show that ipragliflozin, a SGLT2 inhibitor, time-dependently affects behaviour and enhances energy expenditure in normal and type 2 diabetic Goto\u2013Kakizaki (GK) rats, using continuous glucose telemetry. Alongside increased urinary glucose excretion, ipragliflozin increased total food and water intakes in normal and GK rats. In normal rats, ipragliflozin treatment acutely disturbed the circadian rhythms of food and water intakes, activity, and body temperature. Subsequently, these rhythms gradually returned towards a normal state. However, activity and body temperature remained suppressed. In GK rats, ipragliflozin did not affect circadian rhythms. Blood glucose values assessed by glucose telemetry were significantly reduced in both ipragliflozin-treated groups. Despite these behavioural and glycaemic changes, ipragliflozin significantly increased oxygen consumption during dark and light periods in both groups. Ipragliflozin reduced body weight in normal rats only. Thus, ipragliflozin decreases blood glucose beyond compensatory hyperphagia in normal and GK rats, resulting in enhanced basal energy expenditure, despite acutely altering circadian rhythms in normoglycaemic individuals.<\/jats:p>","DOI":"10.1038\/s41598-017-12106-y","type":"journal-article","created":{"date-parts":[[2017,9,13]],"date-time":"2017-09-13T15:17:57Z","timestamp":1505315877000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Time-dependent effects of ipragliflozin on behaviour and energy homeostasis in normal and type 2 diabetic rats: continuous glucose telemetry analysis"],"prefix":"10.1038","volume":"7","author":[{"given":"Hiroyuki","family":"Iuchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaya","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Matsutani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Kayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norihiko","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susumu","family":"Minamisawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunori","family":"Utsunomiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,9,19]]},"reference":[{"key":"12106_CR1","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.diabres.2017.03.024","volume":"128","author":"K Ogurtsova","year":"2017","unstructured":"Ogurtsova, K. et al. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Research and Clinical Practice \n                           128, 40\u201350 (2017).","journal-title":"Diabetes Research and Clinical Practice"},{"key":"12106_CR2","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/S0140-6736(10)62037-5","volume":"377","author":"MM Finucane","year":"2011","unstructured":"Finucane, M. M. et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9\u00b71 million participants. Lancet \n                           377, 557\u2013567 (2011).","journal-title":"Lancet"},{"key":"12106_CR3","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. 7. Obesity Management for the Treatment of Type 2 Diabetes. Diabetes Care \n                           40, S57\u2013S63 (2017).","DOI":"10.2337\/dc17-S010"},{"key":"12106_CR4","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s13300-017-0280-5","volume":"8","author":"G Carls","year":"2017","unstructured":"Carls, G., Huynh, J., Tuttle, E., Yee, J. & Edelman, S. V. Achievement of Glycated Hemoglobin Goals in the US Remains Unchanged Through 2014. Diabetes Therapy \n                           8, 863\u2013873 (2017).","journal-title":"Diabetes Therapy"},{"key":"12106_CR5","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/nrd3180","volume":"9","author":"EC Chao","year":"2010","unstructured":"Chao, E. C. & Henry, R. R. SGLT2 inhibition\u2013a novel strategy for diabetes treatment. Nat Rev Drug Discov \n                           9, 551\u2013559 (2010).","journal-title":"Nat Rev Drug Discov"},{"key":"12106_CR6","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1111\/jdi.12156","volume":"5","author":"A Kashiwagi","year":"2014","unstructured":"Kashiwagi, A., Kazuta, K., Yoshida, S. & Nagase, I. Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus. J Diabetes Invest \n                           5, 382\u2013391 (2014).","journal-title":"J Diabetes Invest"},{"key":"12106_CR7","doi-asserted-by":"publisher","first-page":"373","DOI":"10.14740\/jocmr2492w","volume":"8","author":"K Iemitsu","year":"2016","unstructured":"Iemitsu, K. et al. Factors Influencing Changes in Hemoglobin A1c and Body Weight During Treatment of Type 2 Diabetes With Ipragliflozin: Interim Analysis of the ASSIGN-K Study. J Clin Med Res \n                           8, 373\u2013378 (2016).","journal-title":"J Clin Med Res"},{"key":"12106_CR8","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.2337\/dc15-0355","volume":"38","author":"G Ferrannini","year":"2015","unstructured":"Ferrannini, G. et al. Energy Balance After Sodium\u2013Glucose Cotransporter 2 Inhibition. Diabetes Care \n                           38, 1730\u20131735 (2015).","journal-title":"Diabetes Care"},{"key":"12106_CR9","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1038\/oby.2012.59","volume":"20","author":"JJ Devenny","year":"2012","unstructured":"Devenny, J. J. et al. Weight Loss Induced by Chronic Dapagliflozin Treatment Is Attenuated by Compensatory Hyperphagia in Diet-Induced Obese (DIO) Rats. Obesity (Silver Spring) \n                           20, 1645\u20131652 (2012).","journal-title":"Obesity (Silver Spring)"},{"key":"12106_CR10","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/S0140-6736(11)60812-X","volume":"378","author":"DKDH PhD","year":"2011","unstructured":"PhD, D. K. D. H. et al. Obesity 3 Quantification of the effect of energy imbalance on bodyweight. The Lancet \n                           378, 826\u2013837 (2011).","journal-title":"The Lancet"},{"key":"12106_CR11","first-page":"1","volume":"26","author":"JH Shah","year":"1977","unstructured":"Shah, J. H., Wongsurawat, N., Aran, P. P., Motto, G. S. & Bowser, E. N. A method for studying acute insulin secretion and glucose tolerance in unanesthetized and unrestrained rats. The effect of mild stress on carbohydrate metabolism. Diabetes \n                           26, 1\u20136 (1977).","journal-title":"The effect of mild stress on carbohydrate metabolism. Diabetes"},{"key":"12106_CR12","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1177\/1932296815586424","volume":"9","author":"R Brockway","year":"2015","unstructured":"Brockway, R. et al. Fully Implantable Arterial Blood Glucose Device for Metabolic Research Applications in Rats for Two Months. Journal of Diabetes Science and Technology \n                           9, 771\u2013781 (2015).","journal-title":"Journal of Diabetes Science and Technology"},{"key":"12106_CR13","doi-asserted-by":"publisher","first-page":"e0157672","DOI":"10.1371\/journal.pone.0157672","volume":"11","author":"K Atageldiyeva","year":"2016","unstructured":"Atageldiyeva, K. et al. Sodium-Glucose Cotransporter 2 Inhibitor and a Low Carbohydrate Diet Affect Gluconeogenesis and Glycogen Content Differently in the Kidney and the Liver of Non-Diabetic Mice. PLoS ONE \n                           11, e0157672\u201317 (2016).","journal-title":"PLoS ONE"},{"key":"12106_CR14","doi-asserted-by":"publisher","first-page":"e0150756","DOI":"10.1371\/journal.pone.0150756","volume":"11","author":"Y Chiba","year":"2016","unstructured":"Chiba, Y. et al. Dapagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, Acutely Reduces Energy Expenditure in BAT via Neural Signals in Mice. PLoS ONE \n                           11, e0150756\u201313 (2016).","journal-title":"PLoS ONE"},{"key":"12106_CR15","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2174\/1389450116666150727123115","volume":"16","author":"MA Sullivan","year":"2015","unstructured":"Sullivan, M. A., Harcourt, B. E., Xu, P., Forbes, J. M. & Gilbert, R. G. Impairment of Liver Glycogen Storage in the db\/db Animal Model of Type 2 Diabetes: A Potential Target for Future Therapeutics? Curr Drug Targets \n                           16, 1088\u20131093 (2015).","journal-title":"Curr Drug Targets"},{"key":"12106_CR16","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/cbf.290120306","volume":"12","author":"TM Zhang","year":"1994","unstructured":"Zhang, T. M., Ostenson, C. G. & Malaisse, W. J. Glycogen synthase, glycogen phosphorylase and alpha-amylase activity in homogenates of islets of GK rats: comparison with hepatic and pancreatic extracts. Cell Biochem. Funct. \n                           12, 185\u2013189 (1994).","journal-title":"Cell Biochem. Funct."},{"key":"12106_CR17","doi-asserted-by":"crossref","unstructured":"Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J. Clin. Invest. 124, 509\u2013514 (2014).","DOI":"10.1172\/JCI70704"},{"key":"12106_CR18","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.2337\/db15-1356","volume":"65","author":"E Ferrannini","year":"2016","unstructured":"Ferrannini, E. et al. Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes. Diabetes \n                           65, 1190\u20131195 (2016).","journal-title":"Diabetes"},{"key":"12106_CR19","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ebiom.2017.05.028","volume":"20","author":"L Xu","year":"2017","unstructured":"Xu, L. et al. SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice. EBioMedicine \n                           20, 137\u2013149 (2017).","journal-title":"EBioMedicine"},{"key":"12106_CR20","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ejphar.2016.11.028","volume":"794","author":"F Naznin","year":"2017","unstructured":"Naznin, F. et al. Canagliflozin, a sodium glucose cotransporter 2 inhibitor, attenuates obesity-induced inflammation in the nodose ganglion, hypothalamus, and skeletal muscle of mice. European Journal of Pharmacology \n                           794, 37\u201344 (2017).","journal-title":"European Journal of Pharmacology"},{"key":"12106_CR21","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ejphar.2014.01.040","volume":"727","author":"M Yokono","year":"2014","unstructured":"Yokono, M. et al. SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats. European Journal of Pharmacology \n                           727, 66\u201374 (2014).","journal-title":"European Journal of Pharmacology"},{"key":"12106_CR22","doi-asserted-by":"publisher","first-page":"e30555","DOI":"10.1371\/journal.pone.0030555","volume":"7","author":"Y Liang","year":"2012","unstructured":"Liang, Y. et al. Effect of Canagliflozin on Renal Threshold for Glucose, Glycemia, and Body Weight in Normal and Diabetic Animal Models. PLoS ONE \n                           7, e30555\u20137 (2012).","journal-title":"PLoS ONE"},{"key":"12106_CR23","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1017\/S0007114515000100","volume":"113","author":"M-S Choi","year":"2015","unstructured":"Choi, M.-S. et al. High-fat diet decreases energy expenditure and expression of genes controlling lipid metabolism, mitochondrial function and skeletal system development in the adipose tissue, along with increased expression of extracellular matrix remodelling- and inflammation-related genes. Br. J. Nutr. \n                           113, 867\u2013877 (2015).","journal-title":"Br. J. Nutr."},{"key":"12106_CR24","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s12576-010-0127-6","volume":"61","author":"K Iwata","year":"2011","unstructured":"Iwata, K. et al. Involvement of brain ketone bodies and the noradrenergic pathway in diabetic hyperphagia in rats. J Physiol Sci \n                           61, 103\u2013113 (2011).","journal-title":"J Physiol Sci"},{"key":"12106_CR25","first-page":"E103","volume":"310","author":"L Carneiro","year":"2016","unstructured":"Carneiro, L. et al. Evidence for hypothalamic ketone body sensing: impact on food intake and peripheral metabolic responses in mice. AJP: Endocrinology and Metabolism \n                           310, E103\u201315 (2016).","journal-title":"AJP: Endocrinology and Metabolism"},{"key":"12106_CR26","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.2337\/db15-1356","volume":"65","author":"E Ferrannini","year":"2016","unstructured":"Ferrannini, E. et al. Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes. Diabetes \n                           65, 1190\u20131195 (2016).","journal-title":"Diabetes"},{"key":"12106_CR27","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/0031-9384(72)90044-3","volume":"9","author":"L Hernandez","year":"1972","unstructured":"Hernandez, L. & Briese, E. Analysis of diabetic hyperphagia and polydipsia. Physiol. Behav. \n                           9, 741\u2013746 (1972).","journal-title":"Physiol. Behav."},{"key":"12106_CR28","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.1210\/endo.131.6.1446635","volume":"131","author":"A Sahu","year":"1992","unstructured":"Sahu, A. et al. Neuropeptide Y release from the paraventricular nucleus increases in association with hyperphagia in streptozotocin-induced diabetic rats. Endocrinology \n                           131, 2979\u20132985 (1992).","journal-title":"Endocrinology"},{"key":"12106_CR29","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1111\/j.1365-2826.2006.01470.x","volume":"18","author":"F Maekawa","year":"2006","unstructured":"Maekawa, F. et al. Young Adult-Specific Hyperphagia in Diabetic Goto-Kakizaki Rats is Associated with Leptin Resistance and Elevation of Neuropeptide Y mRNA in the Arcuate Nucleus. J Neuroendocrinol \n                           18, 748\u2013756 (2006).","journal-title":"J Neuroendocrinol"},{"key":"12106_CR30","first-page":"235","volume":"24","author":"JG Bizot-Espiard","year":"1998","unstructured":"Bizot-Espiard, J. G. et al. Diurnal rhythms in plasma glucose, insulin, growth hormone and melatonin levels in fasted and hyperglycaemic rats. Diabetes & Metabolism \n                           24, 235\u2013240 (1998).","journal-title":"Diabetes & Metabolism"},{"key":"12106_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1475-2840-12-1","volume":"12","author":"K Torimoto","year":"2013","unstructured":"Torimoto, K., Okada, Y., Mori, H. & Tanaka, Y. Relationship between fluctuations in glucose levels measured by continuous glucose monitoring and vascular endothelial dysfunction in type 2 diabetes mellitus. Cardiovasc Diabetol \n                           12, 1\u20131 (2013).","journal-title":"Cardiovasc Diabetol"},{"key":"12106_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-015-0233-0","volume":"14","author":"JE Jun","year":"2015","unstructured":"Jun, J. E. et al. The association between glycemic variability and diabetic cardiovascular autonomic neuropathy in patients with type 2 diabetes. Cardiovasc Diabetol \n                           14, 70 (2015).","journal-title":"Cardiovasc Diabetol"},{"key":"12106_CR33","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.2337\/diabetes.52.6.1449","volume":"52","author":"PI Moreira","year":"2003","unstructured":"Moreira, P. I., Santos, M. S., Moreno, A. M., Sei\u00e7a, R. & Oliveira, C. R. Increased vulnerability of brain mitochondria in diabetic (Goto-Kakizaki) rats with aging and amyloid-beta exposure. Diabetes \n                           52, 1449\u20131456 (2003).","journal-title":"Diabetes"},{"key":"12106_CR34","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/dom.12848","volume":"19","author":"D Yabe","year":"2017","unstructured":"Yabe, D. et al. Sodium-glucose co-transporter-2 inhibitor use and dietary carbohydrate intake in Japanese individuals with type 2 diabetes: A randomized, open-label, 3-arm parallel comparative, exploratory study. Diabetes Obes Metab \n                           19, 739\u2013743 (2017).","journal-title":"Diabetes Obes Metab"},{"key":"12106_CR35","doi-asserted-by":"publisher","first-page":"3598","DOI":"10.1210\/jc.2006-0407","volume":"91","author":"CM Brown","year":"2006","unstructured":"Brown, C. M., Dulloo, A. G. & Montani, J.-P. Water-Induced Thermogenesis Reconsidered: The Effects of Osmolality and Water Temperature on Energy Expenditure after Drinking. The Journal of Clinical Endocrinology & Metabolism \n                           91, 3598\u20133602 (2006).","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"key":"12106_CR36","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1248\/bpb.b16-00964","volume":"40","author":"T Takasu","year":"2017","unstructured":"Takasu, T. et al. The Sodium Glucose Cotransporter 2 Inhibitor Ipragliflozin Promotes Preferential Loss of Fat Mass in Non-obese Diabetic Goto-Kakizaki Rats. Biol. Pharm. Bull. \n                           40, 675\u2013680 (2017).","journal-title":"Biol. Pharm. Bull."},{"key":"12106_CR37","first-page":"E373","volume":"306","author":"K Terawaki","year":"2014","unstructured":"Terawaki, K. et al. New cancer cachexia rat model generated by implantation of a peritoneal dissemination-derived human stomach cancer cell line. AJP: Endocrinology and Metabolism \n                           306, E373\u2013E387 (2014).","journal-title":"AJP: Endocrinology and Metabolism"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-12106-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-12106-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-12106-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T11:10:04Z","timestamp":1671793804000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-12106-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,19]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["12106"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-12106-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,19]]},"assertion":[{"value":"4 November 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was funded by Astellas Pharma Inc., Tokyo, Japan. The authors of this manuscript have the following competing interests: MS has participated in speaker\u2019s bureaus\/advisory panels for Sanofi, Daiichi-Sankyo, Astellas, and Tanabe-Mitsubishi. NT has received a research grant and support from Daiichi-Sankyo and Otsuka Pharmaceutical and has participated in speaker\u2019s bureaus organised by Daiichi-Sankyo and MSD. KU has received research support from Terumo, Kowa, Taisho, Arkray, Kyowa Kirin, MSD, Astellas, Boehringer Ingelheim, Ono, Novo Nordisk, Kissei and Tanabe-Mitsubishi and has participated in speaker\u2019s bureau\/advisory panels for Astellas, Astra Zeneca, Kowa, MSD, Eli Lilly, Taisho, Novo Nordisk and Sanofi. The other authors have no conflict of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"11906"}}